A Phase 3 interventional study of Lanthanum carbonate in Kidney Failure, Chronic, sponsored by Shire. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-08.
Sponsored by Shire · Phase 3, Interventional, and Treatment
The purpose of this study is to assess phosphate reduction and control in patients with End Stage Renal Disease treated with lanthanum carbonate
2,085 studies on the registry are indexed under Kidney Failure, Chronic; 260 are open to participants now.
This study's enrollment of 456 is above the median of 55 across 1,557 interventional studies indexed under Kidney Failure, Chronic.
Browse Kidney Failure, Chronic studies →Shire is the lead sponsor of 346 studies on the registry; 2 are open to participants now.
Of its 47 completed or terminated interventional studies of FDA-regulated products, 47 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Change in pre-dialysis serum phosphate levels at Week 3 compared with Week 5
Time frame: Week 3 and Week 5
Treatment emergent adverse events
Time frame: Throughout the study period of approximately 20 months.
No study locations are listed for this record.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shire